entertainment -WSS

entertainment

author：hotspot 2025-08-23 08:57:52 - browse：3848

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

WSS

Addiction experts warn against a second 'war on drugs'

Delta passengers in Vegas fall sick while waiting on flight in triple

Helping hospitals and community health centers plan for resilience

Cytokinetics CEO stresses company can launch heart drug on its own

Second House panel advances two

Judge denies Trump's request for new trial in E. Jean Carroll case

leisure time

entertainment

focus

Alkermes shareholders re

Wearables generate powerful data but its not useful to doctors, yet

Psychedelics group wrestles with new pharma identity

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Walensky prepares to leave CDC — and Congress — behind

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Wildfire smoke exposes gaps in outdoor worker protections

When prostate cancer spreads, where it goes matters

entertainment

Telehealth startups are trying to fill the menopause care vacuum

Solving academic medical centers' existential crisis

When a patient nears the end, a feared therapy can comfort

Judge denies Trump's request for new trial in E. Jean Carroll case

Cytokinetics CEO stresses company can launch heart drug on its own

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

knowledge

focus

hotspot

focus